Palbociclib has antitumour effects on Pten- deficient endometrial neoplasias

Deletion of Pten in CD45-expressing cells leads to development of T-cell lymphoblastic lymphoma but not myeloid malignancies

(2016) C. Mirantes et al.   BLOOD

Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias

(2016) Cristina Mirantes et al.   EUROPEAN JOURNAL OF CANCER

Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases

(2016) Per Hydbring et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Palbociclib (PD0332991)—a Selective and Potent Cyclin-Dependent Kinase Inhibitor

(2016) Amy S. Clark et al.   JAMA Oncology

The history and future of targeting cyclin-dependent kinases in cancer therapy

(2015) Uzma Asghar et al.   NATURE REVIEWS DRUG DISCOVERY

Targeting CDK4 and CDK6: From Discovery to Therapy

(2015) C. J. Sherr et al.   Cancer Discovery

Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present

(2014) Mathew C Casimiro et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells

(2014) N. Eritja et al.   MOLECULAR CANCER THERAPEUTICS

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

(2014) M. Hidalgo et al.   Cancer Discovery

Long-Term Estradiol Exposure Is a Direct Mitogen for Insulin/EGF-Primed Endometrial Cells and Drives PTEN Loss-Induced Hyperplasic Growth

(2013) Nuria Eritja et al.   AMERICAN JOURNAL OF PATHOLOGY

New Roles of Cyclin D1

(2013) Richard G. Pestell   AMERICAN JOURNAL OF PATHOLOGY

One mouse, one patient paradigm: New avatars of personalized cancer therapy

(2013) Prerna Malaney et al.   CANCER LETTERS

An inducible knockout mouse to model the cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias

(2013) C. Mirantes et al.   Disease Models & Mechanisms

Integrated genomic characterization of endometrial carcinoma

(2013) Gad Getz et al.   NATURE

Targeting cell cycle and hormone receptor pathways in cancer

(2013) C E S Comstock et al.   ONCOGENE

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

(2012) J. P. Leonard et al.   BLOOD

CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy

(2012) A. Kathleen McClendon et al.   CELL CYCLE

Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition

(2012) Jeffry L. Dean et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

(2012) Patrick J. Roberts et al.   JNCI-Journal of the National Cancer Institute

A Novel Three-Dimensional Culture System of Polarized Epithelial Cells to Study Endometrial Carcinogenesis

(2010) Núria Eritja et al.   AMERICAN JOURNAL OF PATHOLOGY

A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model

(2008) E. Menu et al.   CANCER RESEARCH

CDK inhibitors in cancer therapy: what is next?

(2007) Marcos Malumbres et al.   TRENDS IN PHARMACOLOGICAL SCIENCES